Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

FDA Warning for Opioids, Benzodiazepines, Experimental Drug for Alzheimer’s Is Promising, and More

By Eric J. Morley, MD, MS, department of emergency medicine, Stony Brook School of Medicine, New York | on November 14, 2016 | 0 Comment
This Just In
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

FDA Requires Boxed Warning, Medication Guides for Opioids, Benzodiazepines

The prescription of opioids and benzodiazepines in combination has increased 41 percent between 2002 and 2014. The FDA will now be mandating “boxed warnings” on 389 separate products in an effort to decrease this dangerous combination.

You Might Also Like
  • FDA Launches Mobile App to Alert Public About Drug Shortages
  • FDA Asks Drugmakers to Limit Amount of Opioid Drug in Packaging
  • FDA Seeks Suspension of 4,402 Illegal Prescription Drug Websites
Explore This Issue
ACEP Now: Vol 35 – No 11 – November 2016

“A Hopeful Sign”: Experimental Alzheimer’s Drug Shows Promise

A monoclonal antibody that targets amyloid plaques seen in Alzheimer’s shows promise in slowing the typical decline observed with this disease. Hopefully, phase III studies will prove this drug to be beneficial.

Researchers Find Association Between Zika and Guillain-Barre Syndrome

The Zika virus has largely been considered a fairly benign viral illness for men and non-pregnant females. However, a recent case series published in The New England Journal of Medicine indicates that the incidence of Guillain-Barre syndrome is 2.0–9.8 times higher than baseline in seven Latin American and Caribbean countries, and this appears to correlate with Zika infections.

Massachusetts Sees Consultant Availability Decrease Between 2005 and 2014

A recent study in the Annals of Emergency Medicine found a decrease in the availability of many specialty consultants in emergency departments across Massachusetts between 2005 and 2014 despite steadily increasing patient visits. General surgery, neurology, ob-gyn, orthopedics, pediatrics, plastic surgery, and psychiatry were the specialties that saw a decrease.

Illinois Sees Increase in ED Visits After Rollout of Affordable Care Act

A study published in the Annals of Emergency Medicine shows emergency department visits have increased since the implementation of the Affordable Care Act despite no increased rate of hospitalization. It is unclear if these visits were unnecessary and better suited for the primary care setting.

Topics: AddictionAffordable Care ActAlzheimerbenzodiazepineEmergency DepartmentEmergency MedicineFDAOpioidOpioid CrisisPublic HealthResearchSafetyWarningZika

Related

  • Opinion: Physicians Must Reduce Plastic Waste

    December 4, 2025 - 0 Comment
  • October 2025 News from the College

    September 23, 2025 - 0 Comment
  • Emergency Physicians Advocate Addressing Climate Change To Improve Public Health

    August 18, 2025 - 0 Comment

Current Issue

ACEP Now: November 2025

Download PDF

Read More

No Responses to “FDA Warning for Opioids, Benzodiazepines, Experimental Drug for Alzheimer’s Is Promising, and More”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*


Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603